Synergy Pharmaceuticals (Ticker: SGYP)

[private]

Company: Synergy Pharmaceuticals
Ticker Symbol: SGYP
Action: SELL

1/2/13 Update… Just wanted to give you a heads up. Synergy Pharm (SGYP) has been trading up 18-20% in pre-market trading. Looks like they got some positive results!

http://finance.yahoo.com/news/synergy-announces-positive-results-plecanatide-100000622.html

I’m glad we stuck around as the last two days have been great! Right now it looks like it is set to open around $6.20. I got in around $5.15 so that’s a quick 20% advance. I will check out the options activity when
the markets open and most likely will put in a sell today to lock in that gain.

12/22/12 Update… SGYP was down  9 cents for the week or -1.77% for the week.  This one still has quite a bit of upside potential.  This article is a must read: http://seekingalpha.com/article/1069471-synergy-pharmaceuticals-stock-undervalued-ahead-of-3-major-events

12/15/12 Update:  This stock was our one blemish last week. The other three stocks and Infinity (INFI), which was sold on good news were all up double digits.  SGYP was down 1.6% for the week. Synergy’s leading compound plecanatide has been showing promise in treating patients with idiopathic constipation and constipation predominant irritable bowel syndrome.  This stock has a catalyst ahead with a key data release on lead product candidate Plecanatide in the near future.  Insiders are bullish on this one as well.

12/12/12 Update:  Bought in @ $5.15. Stop loss in at $4.25

12/11/12 Our Analysis: Synergy Pharmaceuticals (SGYP)is a Renegade stock with great upside potential. It a bigger winner for November (+40%). The real catalyst event is weeks away with the expectations of a Plecanatide Phase IIb/III results release, and it’s possible that shares could quickly take off. If it reports positive results, then this stock could hit $8-$10. This will be a volatile stock and not for the faint of heart. I am looking to get in under $5.25.

Synergy (SGYP) is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy’s lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal [GI] hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation [CIC] patients. In October, 2011, Synergy initiated dosing of patients in a major Phase IIb/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy’s second GC-C agonist SP-333 is in clinical development to treat inflammatory bowel diseases, and is presently in a Phase I trial in healthy volunteers.

[/private]